Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer

By afschroeder • June 25, 2026

Tsvetkova O, Gil TE, Kassir G, Castanon S, Kollapaneni SS, Han A, Park SJ, Li R, Velez MA, Lisberg AE. Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer. Future Oncol. 2026 Jun 25:1-16. doi: 10.1080/14796694.2026.2685854. Epub ahead of print. PMID: 42345080.

Tags: antibody-drug conjugates (ADC), datopotamab deruxtecan (Dato-DXd), DGSOM Student, EGFR-mutated non-small cell lung cancer, Fellow, General Internal Medicine, Hematology/Oncology, interstitial lung disease (ILD), osimertinib resistance, Publications, treatment sequencing, TROP2, TROPION-Lung trials

Feasibility of Using Clinicians to Code the Actionability of Narrative Comments About Patient Experience for Quality Improvement

Quigley DD, Predmore Z, Panayotou MS, Elliott MN, Hays RD. Feasibility of Using Clinicians to Code the Actionability of Narrative Comments About Patient Experience for[...]

Mechanisms of Benefit in Geriatric Assessment (GA): Approach-Oriented Coping Mediates Outcomes of a GA-Guided Supportive Care Intervention (GAIN-S)

Bergerot CD, Bergerot PG, Razavi M, França MVDS, Cerveira JA, Fuzita WH, Philip EJ, Ferreira CGM, Buso MM, Nipp R, El-Jawahri A, Soto-Perez-de-Celis E, Dale[...]

A Cluster Randomized Controlled Trial to Improve Influenza and Tdap Vaccination Rates for Pregnant Women

Rand CM, Bender R, Albertin C, Schrader ARB, Humiston SG, Olson-Chen C, Westen EA, Chen J, Hsu YJ, Parker Fiebelkorn A, Vangala S, Szilagyi PG.[...]